Phase 4 Obesity Trial, Recruiting NCT05051436 Sponsor: Philip Kern Condition: Obesity
Back to Obesity

Phase 4 Obesity Trial, Recruiting

NCT05051436
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People whose HbA1c blood sugar level falls between 5.7 and 6.4 (a range sometimes called "prediabetes")
  • People whose body mass index (a measure of body weight relative to height) falls between 27 and 45

Who may not be able to join:

  • People who have diabetes
  • People who regularly take any medications used to lower blood sugar
  • People who have any unstable medical condition
  • People who use steroid medications, or who take anti-inflammatory pain relievers (such as ibuprofen) on a daily basis
  • People who have a history of long-term inflammatory conditions
  • People who take blood-thinning medications
  • People for whom the trial medications (mirabegron or tadalafil) would not be considered safe to use (confirm with trial site)
  • People whose doctor running the study considers them to be at too high a risk to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Philip Kern, M.D., University of Kentucky

Phone: 859-218-1397

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Philip Kern
Registry
ClinicalTrials.gov
Start date
13 December 2021
Est. completion
1 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Oral glucose tolerance test; Oral glucose tolerance test

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov